Frontiers
Browse
DataSheet_1_Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.docx (1.8 MB)

DataSheet_1_Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.docx

Download (1.8 MB)
dataset
posted on 2022-04-28, 10:45 authored by Edwards Pradenas, Maria Ubals, Víctor Urrea, Clara Suñer, Benjamin Trinité, Eva Riveira-Muñoz, Silvia Marfil, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Ferran Tarrés-Freixas, Josep Laporte, Ester Ballana, Jorge Carrillo, Bonaventura Clotet, Oriol Mitjà, Julià Blanco
Background

Evidence on the determinants of the magnitude of humoral responses and neutralizing titers in individuals with mild COVID-19 is scarce.

Methods

In this cohort study of mild COVID-19 patients, we assessed viral load (VL) by RT-qPCR at two/three time points during acute infection, and anti-SARS-CoV-2 antibodies by ELISA and plasma neutralizing responses using a pseudovirus assay at day 60.

Results

Seventy-one individuals (65% female, median 42 years old) were recruited and grouped into high viral load (VL) >7.5 Log10 copies/mL (n=20), low, VL ≤7.5 Log10 copies/mL (n=22), or as Non-early seroconverters with a positive PCR (n=20), and healthy individuals with a negative PCR (n=9). Individuals with high or low VL showed similar titers of total neutralizing antibodies at day 60, irrespective of maximal VL or viral dynamics. Non-early seroconverters had lower antibody titers on day 60, albeit similar neutralizing activity as the groups with high or low VL. Longer symptom duration and older age were independently associated with increased humoral responses.

Conclusions

In mild SARS-CoV-2-infected individuals, the duration of symptoms and age (but not VL) contribute to higher humoral responses.

History